Evidence map›Paper›PMID 41696669›Full record

ArticleACG case reports journal2026

Treatment of Steroid-Refractory Immune Checkpoint-Related Hepatitis With Ruxolitinib.

Vivian V Nguyen, Malcolm Wells, Carlos Moctezuma-Velazquez, Matthew R Anaka, John Walker, Ellina Lytvyak, Puneeta Tandon, Rahima A Bhanji, Aldo J Montano-Loza

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vivian V NguyenDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Malcolm WellsDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Carlos Moctezuma-VelazquezDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Matthew R AnakaDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
John WalkerDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Ellina LytvyakDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Puneeta TandonDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Rahima A BhanjiDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.
Aldo J Montano-LozaDivision of Gastroenterology and Hepatology, University of Alberta, Edmonton, Alberta, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of immune-related hepatitis (IRH) is rising due to increasing use of immune checkpoint inhibitors for the treatment of several malignancies. While most cases respond to corticosteroid therapy, some patients require additional immunosuppressive agents, for which evidence to guide management is still evolving. We present the first documented case of ruxolitinib use as a tertiary agent for IRH following failure of corticosteroids and tocilizumab, suggesting a potential role for Janus kinase inhibitors as a rescue therapy for severe IRH.

Indexed as

immune checkpoint inhibitorsimmune-related hepatitisruxolitinibsteroid-refractory hepatitistocilizumab

Identifiers

PMID41696669
PMCPMC12900214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.